Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioNxt Solutions Inc.
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 4, 2026
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
July 6, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
June 15, 2026
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
May 26, 2026
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
May 21, 2026
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
May 20, 2026
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
May 19, 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
May 17, 2026